Literature DB >> 7623000

Circulating immune complexes in chronic hepatitis C.

J F Tsai1, J E Jeng, W Y Chang, M S Ho, Z Y Lin, J H Tsai.   

Abstract

For assessing the role of circulating immune complexes (CIC) in chronic hepatitis C, the relative frequency of CIC was determined in 54 patients with chronic hepatitis C, 15 asymptomatic hepatitis C virus (HCV) carriers, and 54 healthy controls. IgM and IgG containing CIC were studied using both C1q and conglutinin (K) in an immunoglobulin-specific solid-phase enzyme immunoassay. CIC were a common feature of chronic hepatitis C with 96.3% of patients with at least one abnormal test result. The prevalence of elevated IgG-K, IgM-K, IgG-C1q, and IgM-C1q CIC was 70.3%, 50.0%, 64.8%, and 35.1%, respectively. The prevalence of IgG class CIC was higher than IgM class CIC (P = 0.038 for K-CIC and P = 0.01 for C1q-CIC, respectively). There is correlation between IgG-K CIC and IgG-C1q CIC (r = 0.445, P = 0.002), IgG-K CIC and IgM-C1q CIC (r = 0.348, P = 0.020), IgM-K CIC and aspartic aminotransferase (r = 0.321, P = 0.015), IgM-K CIC and alanine aminotransferase (r = 0.301, P = 0.027). Compared to patients with chronic persistent hepatitis and chronic lobular hepatitis, patients with chronic active hepatitis have a higher prevalence of elevated IgG-K CIC (77.2% vs. 40.0%, P = 0.029) and IgM-K CIC (56.8% vs. 20.0%, P = 0.038). The concentration of IgG-K, IgM-K, and IgM-C1q CIC in the former was significantly higher than that in the latter, respectively. In conclusion, IgG class CIC is the major type of CIC in chronic hepatitis C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623000     DOI: 10.1002/jmv.1890460104

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Immune complexes that contain HIV antigens activate peripheral blood T cells.

Authors:  L B Korolevskaya; K V Shmagel; E V Saidakova; N G Shmagel; V A Chereshnev
Journal:  Dokl Biol Sci       Date:  2016-09-07

2.  Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo.

Authors:  A I Sharara; D J Perkins; M A Misukonis; S U Chan; J A Dominitz; J B Weinberg
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

3.  Interaction of immune complexes isolated from hepatitis C virus-infected individuals with human cell lines.

Authors:  Rafael Marino; Leopoldo Deibis; Juan B De Sanctis; Nicolas E Bianco; Felix Toro
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

4.  Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

5.  Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.